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94. INTRODUCTION
Despite the fact, that schizophrenia has assumed an increasingly important place in the research
programs on neurosciences and molecular biology around the world, and also, that a growing body
of evidence suggests that this illness is associated with objective changes in the anatomy and
function of the brain, the etiology and pathophysiology of this devastating disease has remained
unknown. From the very beginning of dementia praecox- and schizophrenia research, right up to
our times, there have been findings suggesting that organic factors contribute to the pathogenesis of
this disease. When first described in the eighteenth century, schizophrenia was believed to be
caused by premature progressive neuronal degeneration (Woods 1998). Before long, infectious
diseases were linked to schizophrenia on an epidemiological basis (Bruce and Peebles 1904). The
pre-eminence of psychoanalytic and social psychiatry in the mid-decades of the last century was
accompanied by a dearth of research interest into the possible neurobiological causes of
schizophrenia and other psyhoses. In the fifties and sixties, neurotransmitter theories evolved along
with the increasing knowledge of dopamine and serotonin and their functions in the central nervous
system (Carlsson et al 1958, Carlsson and Lindqvist 1963, Wooley and Shaw 1954). At the same
time, occasional findings of virus-like particles and viral antibodies in the body fluids of psychotic
patients brought up suggestions of viral or autoimmune involvement in the etiopathogenesis of
schizophrenia (Morozov 1954), and yet another era of enthusiasm in psychoneuroimmunology
occurred following the description of slow viral diseases such as kuru and Creutzfeldt-Jacob disease
in the ’ 70s (Gajdusek et al 1972, Torrey 1988).
Also the neurodevelopmental hypothesis of schizophrenia can be traced back to the first part of the
century (Southard 1915), but it has reached its full-scale popularity during the last two decades.
This theory states that schizophrenia is based on a disturbance of the orderly development of the
brain that takes place long before the symptomatic phase of the illness (Weinberger 1995). The
upward trend of the neurodevelopmental hypothesis is primarily based on neuroradiological
evidence suggesting brain volume loss already at the onset of schizophrenia, and no significant
progression thereafter (Nasrallah et al 1986, Hoffman et al 1991). In the ’ 90s reports of longitudinal
neuroimaging studies with findings of progressive brain alterations have arrived on the scene
(DeLisi et al 1997, Davis et al 1998) proposing that the static neurodevelopmental model of
schizophrenia may be an oversimplification of the puzzle. Recent "two-hit" and "three-hit"
pathophysiological models have been making an effort to explain both the contribution of neonatal
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and early life complications as well as potential progressive CNS involvement later in the course of
the illness (Impagnatiello et al 1998, McCarley et al 1999, Keshavan 1999). These comprehensive
hypotheses also attempt to give an alternative explanation for the confusing inconsistency and
contradiction that have been characteristic for findings in the field of schizophrenia research. They
emphasize the heterogeneity of miscellaneous etiological factors participating in the cascading
course of the disease process, instead of purely explaining these discrepancies basing on the
heterogeneity of the disease as a nosological entity.
The occasional cytological findings of the peripheral blood investigations of schizophrenic patients
have been inconsistent, or they have been based on the repeated trials of a small number of
researchers and laboratories (Nikkilä 1997). Therefore, these reports have not offered any
progressive channels of research efforts concerning schizophrenia, in spite of their potential
importance. Another disadvantage has been the deficiency of cerebrospinal fluid studies, which has
left open the question of the potential role of CNS immunocompetent cells in the pathophysiology
of schizophrenia. The requirement for cytological investigations within the CNS body compartment
in schizophrenia arises from the rapidly increasing knowledge of the central position of
mononuclear cells and microglia in the etiopathogenesis of a multiplicity of CNS diseases
(Kreutzberg 1996, Fitch and Silver 1997, Persidsky et al 1999).
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5. REVIEW OF THE LITERATURE
5.1. Schizophrenia
5.1.1. Genetics
Family, twin and adoption studies on schizophrenia have demonstrated that schizophrenia tends to
cluster in families and to have an important genetic component (Tienari et al 1994, Sham et al 1994,
Wahlberg et al 1997). Although the schizophrenia susceptibility genes are still to be identified,
extensive linkage analyses have recently suggested that these genes may be present on
chromosomes 5q, 6p, 8p, 13q, 18p, and 22q. (Shastry 1999, Turecki et al 1997, Bassett and Chow
1999). Incomplete penetrance and environmental forms of phenocopies leave room also for other
influences, and schizophrenia is generally thought to arise as a result of interactions between
genetic vulnerability and environmental risk factors (Yolken and Torrey 1997, vanOs and Marcelis
1998). Nevertheless, no definite association of particular gene or specific environmental factor with
schizophrenia have emerged at present. Genes for differentiation, growth, direction, and repair of
axonal connections within the CNS have been suggested for the focus of genetic studies in order to
clarify the possible connection between structural brain deviation and genetics in schizophrenia
(DeLisi 1999).
5.1.2. Epidemiology
Epidemiologic studies have revealed a predominance of winter or early spring month birth rates
among schizophrenics in the northern hemisphere (Torrey et al 1997). There are also indications
pointing to the possible effect of socioeconomic class (Harvey et al 1996, Mäkikyrö et al 1997),
ethnic origin and immigration (Harrison et al 1988, Wessely et al 1991, Selten et al 1997), as well
as rural vs. urban distribution (Widerlov et al 1997, Mortensen et al 1999) on the incidence of
schizophrenia. Epidemiological data from a Finnish birth cohort exposed to a type A2 influenza
epidemic in 1957 revealed an elevated risk of adult schizophrenic outcome among those who were
in their second trimester of fetal development at the time of exposure (Mednick et al 1988). This
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finding has led to numerous studies on the effect of intrauterine infection on the etiopathogenesis of
schizophrenia (Adams et al 1993, McGrath and Castle 1995). Although the recent negative findings
do not support an association between in-utero exposure to influenza and schizophrenia
(Westergaard et al 1999, Grech et al 1997, Selten et al 1999), the question of a possible relationship
of infective agents to the early events of neurodevelopmental processes is still unsolved.
5.1.3. Neurochemistry
The majority of neurochemical investigations of schizophrenia have been directed towards
monoamine mechanisms (dopamine, noradrenaline, serotonin), amino acid neurotransmitters
(gamma-aminobutyric acid, glutamate) and neuropeptides. Emerging knowledge about the
interactions between different neurotransmitters in complex neurocircuits has diversified the targets
of interest in the neurochemical research on schizophrenia. Particularly dopamine-serotonine
(Boulenguez et al 1996; Kapur and Remington 1996; Lieberman et al 1998) and dopamine-
glutamate (Fitzgerald et al 1995; Glenthoj and Hemmingsen 1999) interactions have aroused
interest.
The dopamine theory of schizophrenia has persisted as the predominant neurochemical hypothesis
for three decades. This hypothesis of excessive dopaminergic function in the CNS of schizophrenic
patients has received strong support from clinical trials with neuroleptic drugs which inhibit the
dopamine-induced stimulation of adenylate cyclase (Clement-Cormier et al 1974), and displace the
high-affinity binding of ligands to the dopamine receptor (Seeman et al 1975). The selective
therapeutic efficacy of the optical isomer of the neuroleptic flupenthixol (as compared to 
isomer, a less potent inhibitor of adenylate cyclase and a weaker dopamine receptor blocking
agent), has supported the view that the neuroleptic effect is based on dopamine effects (Johnstone et
al 1978). The knowledge of the anatomy and pharmacology of the subtypes of dopamine receptors
has increased during the ' 90s (Seeman et al 1993, Ricci and Amenta 1994, Hietala and Syvälahti
1996), and the multiplicity of D2-like receptors has been linked to divergent neuroanatomic sites of
suspected pathology in schizophrenia (Ariano et al 1992, Seeman 1992). Joyce et al (1997) have
hypothesized that D2 receptors in the basal ganglia are the likely site of extrapyramidal symptoms
and not antipsychotic effects, and D3 receptors of the mesolimbic system are a likely site of
antipsychotic effects, and D2 and D4 receptors in the medial temporal lobe and limbic cortical areas
are the sites of additional antipsychotic effects.
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The interest in the potential role of serotonin (5-HT) in the pathophysiology of schizophrenia,
which emerged originally in 1954 (Wooley and Shaw) has been renewed in recent years. Atypical
antipsychotic drugs have proved to be potent 5-HT receptor antagonists and relatively weaker
dopamine D2 antagonists (Meltzer 1995), and molecular biological studies have indicated that
allelic variations of 5-HT receptor genes may affect susceptibility to schizophrenia and clinical
response to atypical antipsychotics (Busatto and Kerwin 1997). In addition to proposals that 5-HT
receptors could be critical sites of antipsychotic action, also the impact of serotonin on
neurodevelopment has been brought up (Lieberman et al 1998).
The psychotomimetic effects of phencyclidine, a glutamate antagonist, have been taken to suggest
that schizophrenia involves reduced brain glutamate function (Castellani et al 1982). The possible
importance of glutamate in the pathophysiology of schizophrenia has been suggested on the basis of
findings from post mortem studies (Kerwin et al 1990, Deakin 1994). Glutamatergic abnormalities
in the anterior temporal cortex of schizophrenic subjects have been suggested to result from the
degeneration of fronto-temporal projections (Deakin and Simpson 1997). Also functional imaging
studies have provided evidence that glutamate may be involved in schizophrenia, and diminished
glutamatergic neurotransmission in the hippocampal glutamate-mediated efferent pathways and
cerebral dysfunction in the hippocampus and its target areas have been proposed to explain some of
the clinical manifestations of schizophrenia (Tamminga 1999).
5.1.4. Neuroimmunology
The immune system has been a subject of investigation already from the early days of
schizophrenia research. In the beginning of the 19th century some clinical observations were made
regarding leukocytosis and elevated temperature at the acute phase of dementia praecox(Bruce and
Peebles 1904), decline of the total number of white blood cells either at recovery or as the disease
became chronic, psychoses associated with some cases of influenza epidemics (Menninger 1928),
and schizophrenia-like psychotic symptoms in conditions resulting from encephalitis (McCowan
and Cook 1928). These findings led to first immunological theories on schizophrenia, regarding it
more or less as a derivative of contagious diseases.
The first reports of the presence of antibrain antibodies in schizophrenic patients came out in 1937
(Lechmann-Facius 1937). Some later studies have supported these findings (Heath and Grupp 1967,
DeLisi et al 1985), but also contradictory reports have been published (Schott et al 1998). However,
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the autoimmune hypothesis of schizophrenia has survived for decades, not least due to findings of
immunoglobulin deviations (DeLisi and Crow 1986, Noy et al 1994), antinuclear antibodies
(Ganguli et al 1993), autoimmune-associated B cell subsets (McAllister et al 1989), autoantibodies
against heat-shock proteins (Kilidireas et al 1992), HLA antigen associations (Wright et al 1996,
Lahdelma et al 1998), and cytokine production abnormalities (Muller et al 1999).
The first reports of nuclear changes in the peripheral blood lymphocytes of schizophrenic patients
were published already in 1962 (Kamp). Soon afterwards more morphological aberrations were
detected (Fessel and Hirata-Hibi 1963) and later Hirata-Hibi named the predominant atypical
lymphocyte type the P cell (Hirata-Hibi et al 1982). The main identifying features of this stimulated
cell are its leptochromatic nuclear structure and high cytoplasmic basophilia (Hirata-Hibi and
Hayashi 1992). These cells have also been found in some relatives of schizophrenic patients and in
patients with myasthenia gravis and rheumatoid arthritis. The significance and specificity of these
findings are somewhat ambiguous, but e.g. viral involvement and reaction to mitogenic agents or
antigens could be possible explanations for the appearance of these cells. Recently, Kokai et al
(1998) have reported significantly elevated numbers of lymphoblasts and activated lymphocytes in
psychotic patients by using phase-contrast microscopy combined with a fluorescent staining
technique.
McAllister et al (1989) have reported a subgroup of schizophrenic patients who had increased levels
of circulating CD5+ lymphocytes. These data could support a possible autoimmune cause for
schizophrenia, because populations of these cells have been shown to be elevated in autoimmune
disorders such as rheumatoid arthritis, progressive systemic sclerosis, and Sjögren’s syndrome. Two
later studies have investigated CD5+ cells in schizophrenia, one with negative findings (Ganguli
and Rabin 1993) and the most recent one supporting the original observation (Printz et al 1999).
There are several reports on various alterations in the distribution of lymphocyte subsets in the
peripheral blood of schizophrenic patients. The findings from these studies have, however, been
contradictory, expressing both high and low CD4+/CD8+ ratios, or no changes at all (DeLisi and
Wyatt 1982, Kaufmann et al 1987, Villemain et al 1989, Masserini et al 1990, Schattner et al 1996,
Cazzullo et al 1998, Printz et al 1999, Sperner-Unterweger et al 1999). One explanation for the
deviations between different studies and patient materials may be due to some kind of 'on' and 'off'
switches of immune responses during the course of illness. It is also possible that the
immunological aberrations are more established among the patients with an advanced form of the
disease, while the acute first episode is influenced by a variety of mechanisms affecting the
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immunological response. The numbers of total T cells and CD4+ cells have been shown to increase
in the course of clinical improvement (Muller et al 1991), and a positive family history of
psychiatric diseases seems to correlate with the high number of CD4+ cells and a higher
CD4+/CD8+ ratio (Muller et al 1993).
Natural killer (NK) cells, functioning in the vanguard of immune defences against tumors and viral
infections, tend to lose a part of their activity in connection with depressive disorders (Caldwell et
al 1991, Zisook et al 1994). Some studies have revealed no mean differences in NK cell activity
between the schizophrenic or schizoaffective patient groups and their controls (McDaniel et al
1992), but there are also reports of depressed NK cell activity in schizophrenic patients that could
be the result of interaction between various factors such as psychotropic medication and physical
restraint (Abdeljaber et al 1994). Sasaki et al (1994) found in their follow-up study that after acute
exacerbation of schizophrenia, the NK activity was significantly lower on admission than after four
and eight weeks from admission. Continuous exposure to phenothiazines may lead to enhancement
of NK cytotoxicity. Urch et al (1988) have described reduced NK activity in both depressive and
schizophrenic patients, but medical treatment improved the NK activity only in the schizophrenic
patient group. In 1999 Sperner-Unterweger et al have detected reduced amounts of NK cells in the
acute state of schizophrenic psychosis, and a normalization of the cell number during treatment in
first episode patients; in the chronic group the initially low number of NK cells normalized over
time.
It seems possible that the alterations in NK cell activity are not specific to schizophrenia, and the
endocrinological and noradrenergic aberrations or stress effects may contribute to the above-
mentioned abnormalities both in schizophrenia and affective disorders.
High titers of interferons and enhanced production of interferon -γ were detected already 15 years
ago (Preble and Torrey 1985), but later studies were contradictory (Rimón et al 1985, Rimón and
Ahokas 1987). Katila et al (1989) have reported a diminished ability of leukocytes from
schizophrenic patients to produce interferon alpha and gamma. Arolt et al (1997) have reported a
lowered production of IFN-γ in acutely ill schizophrenic individuals. IL-2 has been the most studied
interleukin in the field of schizophrenia research. On the serum level, decreased production of
interleukin-2 has been detected (Ganguli et al 1992, Yang et al 1994), and increased serum
concentrations of interleukin-2 receptor (Barak et al 1995) and interleukin-6 (vanKammen et al
1999). Levels of CSF interleukin-2 appear to be affected by relapse mechanisms, while peripheral
blood levels are not. These changes are specific to interleukin-2, since levels of interleukin-1 alpha
seem to be affected by medication withdrawal but not by a change in clinical state (McAllister et al
1995). Circulating levels of TNF alpha have been significantly higher in patients than in controls
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(Naudin et al 1996) and it has been hypothesized that TNF alpha and IL-6 reflect the genetic
background of disease susceptibility (Naudin et al 1997).
Chemoattractant cytokines, the chemokines, have an important role in the early events of
inflammation (Wolpe et al 1988, 1989). They are involved in the inflammatory host responses to
foreign pathogens by attracting and stimulating leukocytes. Macrophage inflammatory protein 1
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been detected in inflammatory CNS diseases (Schall et al 1994, Prieschl et al 1995, Miyagishi et al
1995). Ishizuka et al (1997) have immunohistochemically examined brain tissues from patients with
schizophrenia, and have detected glial cells and neurones in the cortex to stain positively for MIP-1
alpha.
Neopterin is a heterobicyclic pteridine compound that is synthesized and excreted by activated
macrophages (Huber et al 1984). The activation of the cell-mediated immunity, including viral or
bacterial infections, inflammatory reactions and autoimmune diseases increases the neopterin levels
in body fluids (Fahey et al 1990, Hagberg et al 1993). Sperner-Unterweger et al (1989, 1992) have
reported that, in comparison with healthy subjects, schizophrenic patients show significantly lower
urinary levels of neopterin at hospital admission, and that the neopterin concentrations tend to
increase during the first days of treatment. Dunbar et al (1992) found no difference between the
neopterin concentrations of schizophrenic patients and normal controls, measured both in plasma
and urine. The result was the same in the study of Schattner et al (1996), when neopterin was
measured from serum samples. There is one report on increased neopterin levels in the serum of
acutely ill and recovered schizophrenic patients by Korte et al (1998).
The data on immunological abnormalities in schizophrenia have mainly been based on peripheral
blood studies. The few cerebrospinal fluid approaches have concentrated on immunoglobulins
(Solomon and Amkraut 1981, Muller and Ackenheil 1995) and cytokines (DeLisi 1996). There are
special technical demands affecting especially cytological examination of the cerebrospinal fluid
(CSF), e.g. the low total cell count and rapid postpunctional degeneration of the cells (Yam et al
1987), that have made CSF studies difficult to perform. Nevertheless, the requirements for the CSF
approach arise from several CNS studies that have emphasized the ’immune privilege’ of the brain
(Streit et al 1988), and the communicative functions of the blood-brain-CSF barrier (BBB) between
the CNS and the periphery (Nathanson and Chun 1989, Yamada et al 1992). The requirements also
arise from the fact that in certain neuroimmunological diseases, e.g. multiple sclerosis (Merelli et al
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1991) and myasthenia gravis (Müller et al 1990), the changes in the cerebrospinal fluid (CSF) cells
are not directly reflected in peripheral blood.
5.1.5. Neuropathology
The first neurohistological study on psychotic patients who could be considered schizophrenics was
conducted by Alois Alzheimer in 1887. He described abnormal cortical nerve cells and cortical
alterations which were not associated with gliosis. From the first half of the 19th century to the year
1958 cortical atrophy and alterations in basal ganglia and thalamus were reported on several
occasions (Falkai and Bogerts 1995). These early neuropathological findings were later regarded as
postmortem artefacts (Peters 1967).
The emergence of new brain imaging techniques in the 1980s marked also the start of a new era of
neuromorphological studies in the field of schizophrenia research. These recent postmortem studies
have particularly pointed to the limbic system as a major locus of pathology in the CNS of
schizophrenic patients. The findings have been: reduced volumes or cross-sectional areas of
hippocampus and parahippocampal gyrus (Falkai and Bogerts 1986, Brown et al 1986, Jeste and
Lohr 1989), reduced cell numbers, cell size or white matter in these areas (Falkai et al 1988, Benes
et al 1991a, Heckers et al 1991), and abnormal cell arrangements in hippocampus or entorhinal
cortex (Arnold et al 1991). Other findings in limbic brain regions have been left temporal horn
enlargement (Bogerts et al 1985, Crow et al 1989) and increased vertical axon numbers and deficits
in small interneurones in the cingulate gyrus (Benes et al 1987 and 1991, Benes and Bird 1987).
Cortical detections include lower neuronal densities and deficits in small interneurones in the
prefrontal cortex and anterior cingulate gyrus (Benes et al 1986 and 1991b), and higher densities of
glial and neuronal cells in some prefrontal areas (Selemon et al 1995 and 1998). The studies of
basal ganglia, corpus callosum and thalamus have given inconsistent and discrepant findings, and
postmortem studies in general have been heavily criticized due to possible artefacts (shrinkage and
swelling of brain tissue) and small sample sizes (Bogerts 1993, Falkai and Bogerts 1995, Harrison
1999). One of the most indisputable findings has been the failure to find excessive gliosis in
postmortem studies using either immunochemical staining for glial fibrillary acid protein (Roberts
et al 1986, Stevens et al 1988, Falkai et al 1999) or Nissl staining (Falkai et al 1988, Pakkenberg
1990).
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5.1.6. Neuroimaging
MRI studies have presented general loss of brain tissue (Gur and Pearson 1993, Andreasen et al
1994) and gray matter deficits (Woods and Yurgelun 1991, Zipursky et al 1992, Gur et al 1999) in
the brains of schizophrenic patients. The temporal lobe has been the brain parenchymal region with
the most consistently documented abnormalities (Turetsky et al 1995, McCarley et al 1999) and
especially hippocampus, amygdala and parahippocampal gyrus seem to be affected (McCarley et al
1999). Some researchers have suggested that these changes are nonprogressive and may signify a
period of dysregulated brain development in early life (Pfefferbaum and Zipursky 1991, Lim et al
1996). Recently, reports on the correlation between the extent of macroscopic brain alterations and
the duration of the psychotic disease have emerged (DeLisi et al 1997, Jacobsen et al 1998,
Rapoport et al 1999), thus implicating the contribution of a chronic or remitted progressive
pathophysiological process in the CNS of schizophrenic patients.
Functional neuroimaging studies (PET, SPECT, fMRI, MRS, MEG) have produced mostly
contradictory or doubtful findings (Weinberger and Berman 1996, Zakzanis and Heinrichs 1999).
Most studies have suggested low glucose metabolism in frontal areas, but it seems that
hypofrontality, at least in young acute unmedicated schizophrenic patients, is a result of the inability
to activate frontal regions during cognition, rather than a baseline decrease in frontal activity.
(Parellada et al 1998). Neurochemical brain imaging findings point to elevated striatal D2 receptor
density in some patients, unaffected cortical 5-HT2A receptors, and decreased levels of NAA (N-
acetyl-aspartate) in the hippocampus and frontal cortex of schizophrenic patients (Soares and Innis
1999). MEG recordings during transitory auditory hallucinations have revealed response delays in
schizophrenic patients, suggesting parallel activity on the auditory cortex (Tiihonen et al 1992).
Some MEG studies also point to abnormalities of the consecutive preconscious auditory processing
in schizophrenia (Pekkonen et al 1999).
5.2. Cerebral blood flow, blood-brain barrier and cerebrospinal fluid
Although the global blood flow of the brain is well autoregulated in the range of 60 to 160 mm Hg
arterial blood pressure, the regional cerebral flow fluctuates with regional metabolic activity. Brain
blood vessels are very sensitive to Pco2 but less sensitive to plasma H+, because H+ cannot get
through the BBB. The majority of cerebral capillaries are of the nonfenestrated type and construct
an effective barrier against many substances. It is penetrated in only a few areas of the brain. The
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BBB is a semipermeable cell layer (the interior wall) of blood vessels in the central nervous system.
BBB prevents large molecules, immune cells, and all potentially detrimental substances and foreign
organisms (e.g. pathogens) from passing out of the bloodstream and into the CNS (Montemurro and
Bruni 1988, Kiernan 1998).
The intermittent capability of solutes, pathogens and cells to cross the BBB indicates an active
interaction of endothelium with pathogens and immunocompetent cells before they can penetrate
the CNS. The lectin-solute conjugates take an axoplasmic pathway that is comparable but not
identical to that followed by viral particles during their retrograde or anterograde transit through the
axoplasm. The viruses are transferred to other neurons transsynaptically basically in the same way
as the conjugates, but the receptor-mediated transport used by viruses is more specific. Nerves are
implicated in both the entry and outlet of antigens into and out of the brain. Antigens generated
within the CNS have competence to flight from the brain to lymphoid tissue by passing into the
fluid around a cranial nerve and further via the lymph into lymph nodes to start an immune response
involving the CNS (Brightman et al 1995).
The CSF is a transparent colourless fluid with a specific gravity (1.004 - 1.007 g/cm3) somewhat
greater than water. The normal pressure of human CSF as measured in the recumbent position by
lumbar puncture varies from 25-70 mm H2O in infants and from 65-195 mm water in adults.
Under normal conditions it contains scarce protein and has a lower pH, and lower concentrations of
glucose, potassium, calcium, bicarbonate and amino acids than blood plasma. However, the sodium,
chloride, and magnesium content is greater in the CSF. A small number of cells is usually present in
the CSF: 0-8 cells/ mm3 in infants and 0-5 cells/mm3 in adults is considered normal (Davson and
Segal 1996).
The total volume of CSF within the ventricular system and the subarachnoid space is estimated to
be 80-150 ml and the ventricular system alone is assumed to contain from 15-40 ml of CSF, and 75
ml surrounds the spinal cord. Under standard conditions, CSF is formed by the choroid plexus
present within the four cerebral ventricles, the choroid plexus of the lateral ventricles producing the
most. The formation rate is approximately 0.35 ml/min or 500 ml/day, and it replaces the total
volume of CSF about 2-3 times over in 24 hours (Nolte 1999). In humans, circadian variation in
CSF production has been demonstrated, involving a nocturnal increase in production that reaches
twice daytime values (Nilsson et al 1992). Especially under pathological conditions, a considerable
amount of CSF may also be produced at sites other than the choroid plexus; the ependymal lining of
the ventricles and the endothelium of brain capillaries have been considered potential sites of
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extrachoroidal CSF production. As much as 12-20% of the total CSF volume may be extracellular
fluid of capillary origin (Nolte 1999).
The circulation of cerebrospinal fluid proceeds from the lateral ventricles into the third ventricle
through the interventricular foramen. A minor reflux of CSF into the contralateral lateral ventricle is
believed to occur. From the third ventricle, the CSF arrives at the fourth ventricle via the narrow
cerebral aqueduct, and CSF leaves the ventricular system at the level of the medulla oblongata
through three apertures: the midline foramen (of Magendie) and the paired lateral foramina (of
Lushka). These apertures open into enlargements of the subarachnoid space known as the cisterna
magna and the cisterna pontis, respectively (Montemurro and Bruni 1988, Kiernan 1998). The
circulation of CSF within the subarachnoid space also follows an arranged course: from the lateral
foramina of Lushka and the cisterna pontis, the CSF flows anteriorly along the base of the brain and
ascends slowly along the Sylvian fissure and the lateral convex and medial surfaces of the
hemispheres. From the midline foramen of Magendie and cisterna magna, the CSF flows forward
over the cerebellar hemispheres toward the tentorial incisure and also downward into the
subarachnoid space surrounding the spinal cord. The downward flow of CSF around the spinal cord
in normal humans has been a subject of debate. There are suggestions that no true spinal flow
occurs other than that afforded by gravity, but also demonstrations of a rapid descent of spinal CSF
that contrasts with a slower endocranial circulation. The significance of a normal downward spinal
flow of CSF is that it provides a substitute path for CSF absorption under certain pathological
conditions, and it also forms the basis for diagnostic CSF sampling from the lumbar cistern. Only a
small amount of CSF is thought to reach the fourth ventricle by ascending the central canal of the
spinal cord. In fact, the central canal of the spinal cord is occluded in most adults after the age of 20
(Davson and Segal 1996, Montemurro and Bruni 1988, Kiernan 1998).
The most important course by which CSF enters the bloodstream is through the arachnoid villi.
These are microscopic projections of pia-arachnoid mater that extend into venous channels
providing CSF-vascular interfaces; the villi are finger-like projections consisting of a cellular and
fibrous connective tissue core surrounding fluid-filled spaces that are continuous with the
subarachnoid space. Villi function as one-way valves returning CSF from the subarachnoid space to
the dural venous sinuses, as the hydrostatic pressure of the CSF usually exceeds venous pressure.
The precise nature of transport between the subarachnoid space, villus spaces and the venous
channels is still disputed. Different pathways of CSF absorption have also been described. Sparse
amounts of CSF are known to be absorbed via pial vessels and across the walls of cerebral
capillaries within the brain parenchyma. Some absorption also occurs via lymphatic channels
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bordering extensions of the subarachnoid space that surround cranial and spinal nerves. The
presence of arachnoid villi and granulations around spinal nerve roots and their proximity to veins
is consistent with the absorption of CSF at spinal cord levels. The involvement of these alternative
routes of absorption is thought to be particularly important under pathological conditions such as
hydrocephalus (Davson and Segal 1996).
The brain and spinal cord are rendered floatable by the CSF medium in which they are suspended.
This supports and protects the nervous system against rapid movements and trauma. The CSF is
considered to be nutritive for both neurons and glial cells, and the CSF provides a vehicle for
removing waste products of cellular metabolism from the nervous system. It thus functions like a
lymphatic system. The CSF also preserves the consistency of the ionic composition of the local
microenvironment of the cells of the nervous system. The extracellular space of the brain freely
interconnects with the CSF compartment and therefore the composition of the two fluid
compartments is similar. The existence of a number of biologically active compounds (metabolites,
neurotransmitters, hormones, releasing factors) within the CSF suggests that it may function as a
transport system. Since the CSF and brain extracellular space are connected, analysis of the
composition of the CSF provides diagnostic information about the normal and pathological states of
the CNS function (Kiernan 1998, Nolte 1999).
5.3. Cerebrospinal fluid cells
The upper limit of the normal total cell count in the CSF of adult individuals varies from 2500 to
5000 cells x 103/l in specimens taken from the lumbar area (Oehmichen 1976), depending on the
method used. Normal CSF contains mononuclear cells, and the granulocytes and red blood cells are
occasional and rare findings. In the normal differential count, two thirds of the CSF mononuclear
cells are lymphoid cells and the remaining one third consists of cells from the mononuclear
phagocyte lineage (monocytoids and macrophages) (Cook and Brooks 1980, Taskinen 1983). The
distribution of CSF mononuclear cells is age-dependent: newborn infants exhibit a reverse
differential count with one third lymphocytes and two thirds monocytoids/macrophages; this
gradually turns into a normal adult-type distribution during childhood and adolescence (Oehmichen
1976, Cook and Brooks 1980).
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The increase in the total number of CSF cells, pleocytosis, is most often associated with the
inflammatory diseases of the CNS (acute bacterial or viral infections), and in some instances with
intracerebral haemorrhages and CNS neoplasms (Taskinen 1983). A normal cell count does not,
however, exclude CNS disease. Pathologic differential counts without pleocytosis have been
detected e.g. in multiple sclerosis, some forms of epilepsy and neoplasms, as well as in the recovery
phase of CNS injuries or infections (Cook and Brooks 1980). Changes in the proportions of CSF
lymphoid cells and mononuclear phagocytes/macrophages may also reflect the activity of the
chronic inflammatory or degenerative diseases.
5.3.1. CSF lymphocytes
The main lymphocyte population of normal CSF consists of small resting lymphocytes, while the
appearance of enlarged, basophilic or activated lymphocytes or plasma cells is usually associated
with CNS immunoactivation (Taskinen 1983). In the CSF the T/B lymphocyte ratio tends to be
higher than in peripheral blood (Oehmichen 1976). Changes in the proportions of T-lymphocyte
subsets, CD4+(helper/inducer) and/or CD8+ (cytotoxic/ suppressor) cells and in the CD4+/CD8+
ratio in the CSF have been reported to occur in various central nervous system diseases of
inflammatory or autoimmune origin (Pirttilä et al 1987, Kölmel and Sudau 1988, Rotteveel and
Lucas 1990). Both upward and downward shifts of CD4/CD8 ratios can be signs of immunological
abnormalities. The ratios have mainly been elevated in most neuroimmunological diseases, whereas
in HIV infection a decreased CD4/CD8 ratio can be observed already at an early stage of the illness
(Müller et al 1993).
5.3.2. CSF mononuclear phagocytes and macrophages
The cells of mononuclear phagocyte / macrophage lineage detected in the CSF have two main tasks:
the removal of foreign material (scavenger function) and the interactions with lymphoid cells
(immunologic function). Experimental models of nerve injury have exposed the critical role of
macrophages in both degenerative and regenerative actions in the nervous system (DeGroot et al
1992). In certain neurological diseases, the action of resident macrophages seems to play a role in
the disappearance of neurons (Streit et al 1988).
Morphologically, immunophenotypically and functionally, the cells of the monocyte/macrophage
lineage are related to microglia (Streit et al 1988, DeGroot et al 1992, Kettenmann et al 1993).
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Microglia form a regularly spaced network of resident glial cells throughout the central nervous
system. Microglial cells appear to have an essential role in the interaction between CNS and the
immune system. This interplay is mediated by neuropeptides, cytokines and other soluble mediators
of intercellular communication (Zielasek and Hartung 1996). Microglial activation tends to occur at
an early stage of CNS response to injury, so that it often precedes the reactions of any other cell
type in the brain. This transformation of microglia from a resting to an activated state occurs in a
relatively stereotypic pattern displaying proliferation, migration, and changes in morphology,
immunophenotype and function. The first stage of activation is non-phagocytic, and in the second
stage the activated microglia transform into phagocytic cells, also known as microglia-derived brain
macrophages. In addition, microglia have a strong antigen-presenting function and a pronounced
cytotoxic function (Kreutzberg 1996). The cytotoxic vs. protective functions of microglia are
modulated by cytokines and neurotransmitters. IFN-γ activates both macrophages (resulting in e.g.
neopterin production in inflammatory responses, Huber et al 1984) and microglia, but other
cytokines, such as TGF-β1 or IL-4, downregulate microglial and macrophage cytotoxicity
(Loughlin et al 1993).
Macrophages and microglia have also been suggested to have neurodevelopmental actions.
Activated microglial cells have been thought to play several important roles in brain tissue
development, associated with programmed cell death. (Streit et al 1988, Kettenmann et al 1993,
Upender and Naegele 1999).
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6. PURPOSE OF THE STUDY
The objective was to investigate possible cytological aberrations within the central nervous system
of schizophrenic patients by analyzing the levels of the main immunocompetent cell categories and
their inflammatory products from samples of cerebrospinal fluid. To elucidate the effect of
psychiatric treatment on these parameters, a follow-up section was included in these studies.
The specific aims were:
1.  To investigate the cerebrospinal fluid cell numbers and distributions in schizophrenic patients
     during an acute psychotic episode.
2. To perform a morphological analysis of mononuclear cells from schizophrenic patients.
3. To clarify T lymphocyte subset proportions in the cerebrospinal fluid of schizophrenic patients
    and to compare them in corresponding peripheral blood analysis.
4. To determine the cerebrospinal fluid concentrations of the inflammatory products neopterin and
    MIP-1α in schizophrenia.
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7. MATERIAL AND METHODS
7.1. Patients
The study protocol was described to the subjects, and their written informed consent was obtained.
The Ethics Committees of Hesperia Hospital and of Helsinki University Hospital gave their
approval.
From a series of 63 acutely psychotic patients admitted voluntarily or involuntarily to Hesperia
Hospital (Department of Psychiatry, Helsinki City Hospital) during the years 1991-1993, 50
individuals (28 women, 22 men) were included in these studies. The DSM-III-R diagnostic criteria
(American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Revised
Third Edition. American Psychiatric Association, Washington, DC, 1987) were applied to confirm
that the psychosis of the patients belonged to the schizophrenia spectrum (schizophrenia,
schizophreniform disorder, schizoaffective disorder). Patients with other diagnoses were ruled out,
as well as subjects with serious physical diseases, alcoholism, or drug abuse. Acute infections were
excluded clinically and by routine laboratory infection markers in peripheral blood and in CSF. The
CSF/serum ratio for albumin was 4.2±1.5 (mean±SD) in the patient group, excluding significant
blood-brain-barrier damage of the patients.
The mean age of the total patient population was 31.9 years (SD 8.2, range 18-53). Twenty-nine
patients were on their first admission and they had not been on neuroleptic medication before. The
remaining 21 patients had been previously treated for at least one psychotic episode (3.2±4.5
episodes including the current one, range 1-26), but they had been drug-free for at least three
months prior to admission. The symptoms of the patients were rated with the 18-item Brief
Psychiatric Rating Scale (BPRS) (Bech et al 1986), rating each item from 0 to 6.
The demographic and clinical characteristics of the patients in each individual study are given in
Tables 1 and 2.
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Table 1. Demographic characteristics of the patients in Studies I-IV
N Female/male Age (means±SD, range)
I 31 15/16 31.2±7.6, 20-54
II 35 16/19 33.3±8.7, 18-53
III 30 17/13 30.9±8.8, 18-43
IVa 11 6/5 31.2±8.8, 18-43
IVb 8 3/5 34.4 ±9.6, 18-43
Table 2. Clinical characteristics of the patients in Studies I-IV
FA/RED BPRS18E HDF CPZeqG
I 18/13 59.411.2 4.12.3 426±288
II 20/15 56.0±14.1 4.4±2.3 377±215
III 17/13 57.5±12.6 4.4±2.4 369±230
IVa 6/5 60.3±11.2 4.5±1.8 390±244
IVb 4/4 58.4±10.6 4.3±1.7 400±288
D
 first admission / re-entry patients,
E
 BPRS scores (means±SD),
F
 days in hospital before sample collection (means±SD)
G
 neuroleptic medication dosage per day in chlorpromazine equivalents (means±SD)
7.2. Reference populations
The control group in Studies I-III consisted of patients examined at the Outpatient Department of
Neurology at the Helsinki University Central Hospital for the following symptoms: headache, leg or
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arm pain and/or paresthesia, vertigo, facial pain, vasovagal attack, hypacusis, and tinnitus. One of
the control subjects had a brain infarction of the right hemisphere nearly two years after CSF
sampling. In the rest of the controls no evidence of inflammatory or CNS disease emerged at
examination during a follow-up period of 2.5 to 6 years. In Study I the control population consisted
of 21 individuals, 6 men and 15 women. The mean age of the reference series was 43 (range 27-64)
years. The control population in Studies II and III consisted of 46 outpatients; the female/male ratio
was 25/21. The mean age of this reference series was 33 (range 18-65) years.
In Study IV the controls were unmedicated, normotensive paid volunteers from the hospital staff.
Subjects with a family history of psychiatric illness in first-degree relatives were excluded.
Psychiatric diagnoses of control subjects were ruled out by the Structured Clinical Interview for
DSM-III (SCID). The control population participating in the neopterin study consisted of 10
persons (3 women and 7 men), aged 34, range 20-57 years, and the MIP-1α study was conducted
with a control group that comprised of three women and five men, aged 31 (range 20-57) years.
Demographic characteristics of reference populations as regards the individual studies are reported
in Table 3.
Table 3. Demographic characteristics of control and reference populations in studies I-IV
N Female/male Age (means±SD, range)
I 21 15/6 43.0±9.8, 27-64
II and III 46 25/21 32.7±9.8, 18-65
IVa 10 3/7 33.6±12.8, 20-57
IVb 8 3/5 31.3±11.7, 20-57
7.3. Collection and preparation of specimens
The collection of CSF and PB samples from the schizophrenic patients was performed on day 4.6±
2.4, range 0-7 days after admission. During this period the patients were medicated with a mean
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neuroleptic dose of 396±242 mg chlorpromazine equivalents. The principal antipsychotics in use
were chlorpromazine and haloperidol. Two patients used additional benzodiazepines and one was
on lithium. No other drugs were administered.
After overnight fasting and 30 minutes’ bed rest, blood was drawn at 8-9 o’clock a.m., and
immediately after that lumbar punctures were performed in lateral decubitus position. The CSF was
collected in fractionated aliquots in chilled tubes. For the quantitative mononuclear cell analysis 1
ml of native CSF was fixed in 1 ml of 96% ethanol and the specimens were filtered through
Millipore filter (Millipore Corp., Bedford, MA, USA) and stained according to the Papanicolaou
method. Cytocentrifuged smears were prepared from samples of 4 ml of unconcentrated CSF in cell
culture medium that was kept on ice and centrifuged ((Shandon Cytospin; 800rpm/8-10min) within
30 minutes in order to prevent postpunctional cell degeneration. The native unconcentrated CSF
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Blood samples were taken from an antecubital vein and promptly centrifuged at 4
o
C at 3000 rpm for
10 minutes. The separated serum was immediately frozen at -70
o
C until assayed. Blood
mononuclear cells were separated from heparinized PB samples by Ficoll-Hypaque density gradient
centrifugation, and cell smears were processed by cytocentrifugation as described above.
Cytocentrifuged CSF samples were stained with May-Grünwald-Giemsa (MGG) and analyzed in
order to observe detailed morphological features of the cells and to exclude samples with red blood
cell contamination; samples with >20 red blood cells / high power (40x) field were rejected.
7.4. Evaluation of total cell count and the differential count of mononuclear cells
The Millipore filtration CSF slides were prepared by commercial Millipore filtration equipment
using cellulose acetate filters. The filtration was assisted with gentle negative pressure. The slides
were stained by the Papanicolaou method, and were examined by light microscopy at 40 x
magnification for quantitative determinations, and at 100 x magnification for counting the main
mononuclear cell distributions. The cells per visual field were counted and the number of total
visual fields were evaluated to determine the absolute cell numbers of each CSF sample. The
differential counts were performed by analyzing at least 100 cells from each slide on a
morphological basis. The method has been described in detail by Kölmel (1977) and Taskinen
(1983).
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7.5. Detailed morphological analysis of mononuclear cells
The morphological details of CSF and PB cells were examined by light microscopy on
cytocentrifuged samples stained by MGG. The objective magnification of 100 x was used, and at
least 60 cells per patient sample were analyzed. On a morphological basis the cells were divided
into mononuclear phagocytes/macrophages and lymphocytes. The lymphocytes were further
categorized as normal or activated, on the basis of their nuclear and cytoplasmic contour and
staining properties. The calibration of microscopic analysis was performed by blind comparison
between two analysts.
7.6. Phenotyping of lymphocytes
Phenotyping of CSF and PB lymphocytes to CD4+ and CD8+ T cells was carried out with the 3-
layer indirect immunoperoxidase technique on air-dried cytocentrifuge smears. The following
primary monoclonal mouse antihuman antibodies were used: leu 3a+3b (Becton Dickinson,
Mountain View, Ca, USA) for detecting CD4+ lymphocytes and OKT-8 (Ortho Diagnostic Systems
Inc., Raritan NJ, USA) for detecting CD8+ cells.
The stained specimens were analyzed by light microscopy at 40x and 100x magnification. From
CSF cell preparations, 68+/-5 lymphocytes were analyzed for each surface marker. As for PB
samples, a total of 100 lymphocytes were counted for each monoclonal antibody.
7.7. Neopterin assay
The HENNINGtest® Neopterin –radioimmunoassay was applied to measure the neopterin levels in
the CSF and serum samples. This RIA method employs the 125I-Neopterin tracer. Samples and
neopterin standards were mixed with tracer and precipitating antiserum, then incubated for one hour
at room temperature under the exclusion of light. After washing and pelleting by centrifugation, the
radioactivity was measured by a gammacounter. The mean count rates of double samples were
related to the count rate of zero standard and the corresponding neopterin concentrations in nmol/l
were read from the standard curve.
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7.8. ELISA for MIP-1alpha
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by the immobilized antibody. Unbound substances were removed by washing, and an enzyme-
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unbound antibody-enzyme reagent, a substrate solution was added to the wells, and color developed
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by a specific stop solution, and the intensity of the color was measured by a microplate reader at
450 nm.
7.9. Statistical methods
Descriptive statistics are given as means±standard deviations (SD) with the exception of Study I, in
which means±SEM (standard error of means) were used and the reference values for T lymphocyte
subsets were obtained from the examinations of the control subjects with the percentile method
(Herrera 1958), which estimates the 95% normal range.
The Mann-Whitney U test, rank transforms and ANOVA were used to study the between group
values and Wilcoxon matched pairs test was the statistical method applied to compare the patients’
CSF cytology before and after treatment. The correlations were statistically analyzed by the
Spearman rank order correlation test.
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8. RESULTS
8.1. T lymphocyte subsets
Comparison of the percentages of CSF lymphocyte subtypes (Study I) separately (CD4+ and CD8+
cells) or the CD4/CD8 ratios between the whole group of schizophrenic patients (N=31) and
healthy controls (N=21), brought forth no statistically significant differences (Table 4). The
schizophrenic patient group exhibited obviously wider ranges (16-73% for CD4+ and 15-52% for
CD8) than did the reference population (27-68% for CD4+ and 21-46% for CD8+). As first-
admission and re-entry patients were analyzed separately, no statistical difference could be detected
between the controls and first-timers (N=18), but in the re-entry group (N=13) the range was more
narrow regarding both CD4+ and CD8+ percentages, and there was a statistically significant
(p=0.022) tendency towards lower CD8+ lymphocyte percentages in the CSF (Table 5).
Determination of the 95% reference limits of the control population, and consideration of the
proportions of both lymphocyte subsets together, revealed the aberrant CD4+ and/or CD8+
distributions in the majority of the patients (23/31; 74%). Remaining below the reference limit was
a more prevalent finding concerning both lymphocyte subtypes. As many as 15/18 (83%) of the
first-admission patients were outside the reference limits, while in the re-entry group 8/13 (62%) of
the patients had CD4+ and/or CD8+ percentages outside the normal range. All the patients with
high CD8+ percentages were from the first-admission group (Figure 1).
There was a negative correlation between the total count of CSF cells and the proportion of CD8+
lymphocytes (r=0.61), and between the patients’ age and CD4+% (r=0.76) or CD4/CD8 ratio
(r=0.67) in the CSF. Female and male patients did not differ in their lymphocyte subtype
presentation in the CSF (		
).
The patients screened for both CSF and PB cells (N=15) expressed alterations in the distribution of
T cell subsets in the CSF, while the T cell subsets in PB were within the reference limits. The
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CD4/CD8 ratios in the CSF were both high and low, while the deviations seen in the PB (5/15)
were above the upper reference limit. No correlative association could be detected between CSF
and peripheral blood lymphocyte subset findings of the patients The correlation coefficients were –
0.21 for CD4+%, 0.11 for CD8+% and 0.05 for CD4/CD8 ratio.
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Figure 1. Percentages of CD4+ and CD8+ lymphocytes in the CSF of first admission
and re-entry patients with acute schizophrenia. Dashed lines show the lower and
upper 95 percentile reference limits of the control subjects.
8.2. Mononuclear cell distribution
The microscopic examination of the CSF Millipore filtration slides from 35 psychotic patients and
46 control individuals (Study II) revealed highly significantly (F-ratio=47.34, df=1, 16, p<0.0001)
elevated proportion of cells morphologically classified as mononuclear phagocytes / macrophages
(Figure 2).
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Figure 2. The distribution of mononuclear phagocytes / macrophages (MP %) in
the cerebrospinal fluid of schizophrenic patients and normal controls.
No statistically significant difference was detected in the total CSF cell counts of patients and
controls (Table 4). The distribution of mononuclear cells was so deviant, however, that in addition
to the proportional difference of mononuclear cells, also the absolute numbers of
monocytes/macrophages were significantly (p<0.001) elevated in the schizophrenic patient group in
spite of the normal total cell count in the CSF (		
). A significant tendency (p<0.05)
towards a higher CSF monocyte / lymphocyte ratio was observed in the re-entry patient group
(N=15) as compared with first-admission patients (N=20) (		
 ). No statistical
differences in the appearance of the mononuclear cells in the CSF could be found with regard to the
sex of the patients. The relative and absolute values for mononuclear cells did not correlate
significantly to the patients’ age, BPRS scores or medication (the duration of medical treatment
prior to sample collection, and the dose of medication in chlorpromazine equivalents).
A statistically significant tendency towards normalization of the cytological picture (i.e. decrease in
the elevated frequency of monocytes/macrophages) was observed in the CSF of those psychotic
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patients who took part in the follow-up section of the study (N=13, df=1, 18, P<0.05) after a few
weeks’ treatment with typical neuroleptics. The absolute numbers of monocytes in the CSF of the
patients did not change significantly in the course of the treatment.
8.3. Morphological analysis of mononuclear cells
Analyzed from the MGG stained cytocentrifuge slides (Study III), the cytological profiles of the
CSF samples from schizophrenic patients (N=30) at the initial phase of hospital treatment differed
clearly from those in the CSF of healthy controls (N=46). The detected dissimilarities concerned
both the differential counts of mononuclear cells (as in Study II obtained with a different
methodology) and the morphological details of the lymphoid cells.
The most outstanding lymphocyte finding was an accumulation of phenotypically deviant cells with
morphological characteristics of activation (Figure 3). The size of these cells ranged from small to
medium and large, and the morphological attributes consisted of basophilic cytoplasm, convoluted
nuclei and an irregular nuclear membrane, prominent nucleoli and dispersed chromatin. All in all,
the morphological features of these cells are typical for stimulated or immunoactivated
lymphocytes, although the majority of these cells in the CSF slides of schizophrenic patients did not
fulfill the size criteria of stimulated lymphocytes. The dominating cell population in the CSF slides
of control individuals represented small, resting lymphocytes; large stimulated lymphocytes were
less frequent, and small to medium-sized lymphocytes with morphological signs of activation were
virtually absent. Pooled together, the proportion of lymphocytes with characteristics of stimulation
or activation (including both "normal" large stimulated cells and "atypical" small to medium-sized
lymphocytes) exceeded the cohort of normal resting lymphocytes in the schizophrenic patient
group. Compared to the controls, the difference was statistically highly significant (p<0.001, Mann-
Whitney U test) (Table 4).
No correlations of lymphocyte activational stage were detected with the patients’ age, BPRS scores,
the absolute number of cells in the CSF, or medicational status (treatment days before sample
collection, and the neuroleptic dose). Female and male patients did not differ from each other as a
group in their expression of lymphocytes with morphological activation signs.
Analysis of the follow-up samples from the patients after 3-4 weeks of hospital treatment with
conventional neuroleptics did not point to significant changes in the lymphocyte profiles during this
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period, whereas the macrophage/lymphocyte distribution exhibited a tendency towards normal
appearance (p<0.05, Wilcoxon matched pairs test). The last-mentioned finding was in line with the
detection of normalization in the CSF cell arrangement during the course of treatment, as observed
from Millipore filtration slides in Study II.
The monocytoid cells of schizophrenic patients represented pleomorphic maturational stages on the
basis of the cytological details (Figure 3). These cells ranged from juvenile mononuclear
phagocytes with a compact kidney shaped nucleus and homogeneous cytoplasm including some
small acidophilic granules to mature macrophages with a lobulated irregular nuclear shape and a
voluminous cytoplasm with numerous vacuoles. Overt lipophages with larger cytoplasmic vacuoles
were rarely seen.
In the schizophrenic patient group, occasionally “rosettes” i.e. aggregates between lymphocytes and
macrophages were encountered in the CSF slides. Sporadic findings of polymorphonuclear
leukocytes comprised less than 1% of the cell populations, both in schizophrenic patients and in
normal controls.
8.4. Levels of Mip-1 α and Neopterin
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course of medical treatment. The concentrations in the group of 8 control individuals were 5.1±0.7
pg/mL (mean±sd). In the patient group (N=8) the corresponding values were 4.7±0.3 pg/mL at
admission, and 4.7±0.4 pg/mL after the treatment period.
The CSF neopterin concentrations of 10 control subjects were 2.9±1.5 nmol/l (mean±sd) and those
of 11 schizophrenic patients beginning their hospital treatment were 2.8±2.2 nmol/l. There was no
statistical difference between the patient and control groups. The follow-up samples of these 11
schizophrenic patients expressed concentrations 2.7±2.1 nmol/l, which did not reach statistical
difference to the neopterin concentrations from either the control population or from the same
patients at admission.
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Table 4. Main results of Studies I-IV concerning the CSF findings of schizophrenic
patients and normal controls (means±SD).
Patients Controls p-values
I N=31 N=21
CD4+ (%) 46±3D 52±2D n.s.
CD8+ (%) 30±2D 33±2D n.s.
CD4/CD8 1.71±0.15D 1.63±0.08D n.s.
II N=35 N=46
Cell count 1466±1070 1359±755 n.s.
Monocytes 53.9±9.1 35.7±13.5 <0.001
Lymphocytes 46.3±9.1 63.9±13.8 <0.001
III N=30 N=46
Resting LyE 45±13 81±8 <0.001
Activated LyE 55±13 19±8 <0.001
IVa N=11 N=10
NeopterinF 2.8±2.2 2.9±1.5 n.s.
IVb N=8 N=8

 F 4.7±0.3 5.1±0.7 n.s.
D
 means±SEM
E
 Ly=lymphocytes (%)
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Table 5. Main results of Studies I-IV concerning the statistically significant CSF
findings of first admission (FA) and re-entry (RE) patients analyzed separately
(percentages, means±SD)
FA RE Difference: FA/RE Difference to
                                                                                                                                   controls
CD8+ 33±3D 26±2D n.s. <0.05 (RE)
Monocytes 49.8±8 58.2.±8.3 <0.05 <0.001 (FA&RE)
Lymphocytes 50.5±7.7 41.8±8.3 <0.05 <0.001 (FA&RE)
Dmeans±SEM
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9. DISCUSSION
9.1. Methodological limitations
In relation to the fact that the patient materials of CSF studies on neuropsychiatric disorders have
generally been heterogeneous and few in number, the quantitative and qualitative characteristics of
the patient and control populations can be regarded as representative in Studies I, II, and III, and
moderate in Study IV. Both first-admission and re-entry patients were included, and the total in
each subgroup was sufficient for statistical comparisons between the groups in the first three
studies. Calculations with correlation coefficients did not point to any significant variations in the
CSF findings, as regards the patients’ age, duration of illness, number of treatment episodes,
medication or clinical status, but in this respect the number of patients can be considered too limited
for drawing reliable conclusions on the role of these factors. The drug-free period of at least three
months prior to hospital admission was an advantage of the patient materials, and it lessens the
possibility of medication effect on the findings of these studies. Unfortunately, medication effect
cannot be ruled out entirely, since the CSF samples could not be obtained before starting the
medical treatment. The treatment period was, however, quite short and the follow-up part of the
studies did not bring out significant changes in cell or cytokine parameters in the course of drug
treatment. An exception was the normalization tendency in the mononuclear cell distribution; this
finding contradicts the expectation of drug-induced immunological aberrations. Furthermore,
previous cytological studies have suggested that short-term medical treatment with conventional
neuroleptics does not significantly enhance the pathological features in lymphocyte populations. A
correlation between the neuroleptic dose and the number of CSF cells has been detected in one
study, but the variation was within normal range, and there was no relationship between the cell
frequency and the duration of medical treatment (Wahlbeck et al 2000.
The reference populations in Studies I, II and III consist of neurological outpatients with mild
symptoms and no evidence of CNS disease. In spite of the fact that these individuals were not
randomly selected healthy subjects, they are to be considered as normal controls due to the thorough
and longitudinal exclusion of any disease process. A possible weakness of these reference groups is
that psychiatric disorders were ruled out by mere clinical estimation and not with a structured
clinical interview, which was the case in the normal control group in Study IV.
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The cytological methods of CSF examinations should be selected on the basis of two requirements:
high cellular yield and minimal cellular artefacts (Kölmel 1976, Taskinen 1983). The application of
flow cytometry (FACS), the method that enables double-staining, was excluded at the pilot phase of
the study, as the total cell counts of the samples were found to be normal or low. The sensitivity of
FACS in the evaluation of diagnostic CSF cytology is relatively low (Cibas 1995), and the methods
derived from immunocytochemistry have been regarded as more reliable for the examination of
surface markers on CSF cells, particularly for samples without pleocytosis (Windhagen et al 1999).
The combination of Millipore filtration and cytocentrifugation is considered to be the optimal
technique for the investigation of CSF mononuclear cells, due to high cellular harvest with the
filtration method and well preserved cytomorphology with cytocentrifugation (Gondos and King
1976, Taskinen 1983, Kobayashi et al 1992). These methods permit the reliable quantification of
CSF cells and the differential count and morphological analysis of mononuclear cells in the CSF, as
well as division into the main lymphocyte subtypes by application of immunoperoxidase staining.
The signs of activation nevertheless remain to be evaluated indirectly on a mere morphological
basis in the absence of double-staining activation markers, which require the use of flow cytometry.
Therefore, it should be borne in mind that the expression 'activated' used in these studies is
associated with the morphological features of the CSF cells, and the activated status of the cells is
not verified by activation markers.
9.2. The subsets of T lymphocytes in the CSF and PB
The results of the T lymphocyte surface antigen study (	
 ) point to alterations of the
immunocompetent cell composition in the cerebrospinal fluid of schizophrenic patients in the acute
phase of the disease. Although the findings concerning CD4 positive and CD8 positive cells and
CD4/CD8 ratios varied widely in the patient group, thus covering the statistical significance of
deviations at group level, the analysis of the proportions of these cell subsets together revealed that
74% of the patients had an abnormal CD4 and/or CD8 composition in their CSF. As both high and
low CD4/CD8 ratios have been detected in a variety of CNS diseases affecting the immune system,
the wide-range finding can be explained by three mechanisms: the heterogeneity of the disease
itself, the variety of factors affecting the immunological response in the acute phase of the psychotic
episode, and the changes in immune reactions during the course of the illness. In this study the
finding of a statistically significant difference in first-admission vs. re-entry patients regarding the
proportion of CD8 positive cells and the smaller variation in CD4+ and CD8+ cells and CD4/CD8
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ratios suggests that the immunological aberrations are more established among the patients with an
advanced stage of the disease.
Previous studies of T lymphocyte subsets in schizophrenia have been conducted on the peripheral
blood level, and they have produced a bulk of contradictory findings. The most recent PB studies
have been more thoroughly planned than the previous ones, and they have produced results which
support the view of immunological aberrations in schizophrenia. However, the ’immune privilege’
of the brain, the communicative functions of the blood-brain-CSF barrier and previous reports on
nonparallel findings of PB and CSF cells in other CNS diseases are facts that may diminish the
reliability of immunological data obtained on the peripheral body compartment. Viewed from this
angle, the finding of lymphocyte deviations in the CSF of schizophrenic patients suggests more
clearly that immunological abnormalities do occur in connection with schizophrenia. Our finding of
no association between the patients’ CSF and PB lymphocyte findings further emphasizes the
superiority of CSF studies over PB analyses in schizophrenia and other CNS diseases.
9.3. The quantitative and proportional cytology of CSF mononuclear cells
The distributions of mononuclear cells in the CSF from schizophrenic patients in S	
  were
almost invariably skewed from lymphocyte domination to macrophage enrichment. This is a
frequent finding in CNS injuries and degenerative CNS diseases, usually accompanied by an
increase in the total number of CSF cells. The absence of pleocytosis and heavy lipophages in the
patient samples of this study make this macrophage accumulation more susceptible to subtle
chronic or subchronic degenerative processes than acute neuronal injuries within the CNS. This
finding lends some support to the hypothesis of slight progressive brain substance loss in the
longitudinal course of schizophrenic psychosis which have been proposed on the basis of several
neuroradiological studies of this illness.
The majority of macrophages detected in the CNS and CSF are considered to be of microglial
derivation (Thomas 1992). This relationship makes the finding of this study potentially important
also from the neurodevelopmental point of view. The microglia network is formed from the
hematopoietic stem cells during fetal development, and various pathophysiological events within
the CNS are able to induce the activation and mobilization of these resting cells into pluripotent
immunocompetent scavengers and defenders with HLA-DR expression and ability to act as antigen-
presenting cells, to have phagocytic capacity, and to produce cytokines and neurotoxins. The CSF
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cell composition with macrophage dominance over lymphocytes is also typical in newborn infants.
This further tempts one to speculate that this finding may be in connection with cells of the
macrophage-microglial lineage participating in the pathophysiology of schizophrenia during CNS
development, or may reflect a genetically transformed immune response to environmental factors.
9.4. Morphological characteristics of CSF lymphocytes and monocytes
From the early ’60s on, the appearance of atypical lymphocytes in blood smear samples from
schizophrenic patients has been a sporadic topic of discussion in the field of schizophrenia research.
This important but debatable finding was introduced by Fessel and Hirata-Hibi, and during the
following three decades Hirata-Hibi has occasionally repeated and defined the presentation of ‘P
cells’. One argument against the ‘P cell’ has been the fact that it has been the finding of one
research group, and there have been no other reports on these cells. The morphological analysis of
MGG-stained cytocentrifuged CSF slides from schizophrenic patients (	
 ) confirm the
findings of Hirata-Hibi et al. concerning the morphologically deviant lymphocytes in schizophrenia.
The appearance of such cells on both sides of the BBB brings up the question of their origin and
relationship to the BBB condition and function. In our study, no protein exudation was detected,
which excludes the possibility of significant BBB damage and passive leakage of cells from one
body compartment to another. On the other hand, active transport by transendothelial migration is
conceivable, since the activation of lymphocytes tends to increase their mobility and to induce
upregulated expression of e.g. adhesion molecules which contribute to cell traffic through the BBB.
The rosette formations between lymphocytes and macrophages detected in this study indirectly
point towards increased lymphocyte adhesiveness, and there are recent reports on elevated
expression of leukocyte adhesion molecules in schizophrenia. The primary source of
morphologically aberrant lymphocytes in schizophrenia is questionable. In this study, the
proportions of activated and atypical lymphocytes in the CSF exceeded those in PB, but this does
not necessarily demonstrate the intrathecal production of this cell line. Further studies of cell
migration and BBB functions are needed to elucidate this question.
The morphological similarity of ‘P cells’ and CD5+ lymphocytes has been suggested by McAllister
et al (1989) in connection with the detection of elevated levels of CD5+ B cells in PB from a
subgroup of schizophrenic patients whose disease was thus considered to have an underlying
autoimmune and/or genetic cause, because populations of these cells have been shown to be
elevated in autoimmune disorders such as rheumatoid arthritis, progressive systemic sclerosis, and
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Sjögren’s syndrome. Recently, Printz et al (1999) have replicated the finding of elevated levels of
CD5+ B lymphocytes in schizophrenia. An additional interesting feature of CD5+ cells is related to
their behavior during ontogenic sequences: the preliminary forms of these cells are transferred from
bone marrow to the retroperitoneal space very early, and they form the main part of B lymphocytes
during fetal development, but after birth their proportion is normally reduced to less than 5%. This
phenomenon may link CD5+ cells to the concept of the neurodevelopmental disorder. The
morphological relationship between CD5+ cells, ‘P cells’ and the activated lymphocytes from CSF
detected in this study requires future studies of the characterization of CSF lymphocytes by using
activation markers, in order to find out whether these cells can be considered as candidates for
cytological derivatives of neurodevelopmental or neurodegenerative processes during the
pathogenetic cascade of schizophrenia.
The stability of the aberrant lymphocyte finding in the CSF from schizophrenic patients in the
course of neuroleptic treatment and clinical improvement may signify that this could be more a trait
than a state marker of the disease, and link it to the genetic background of schizophrenia. Previous
detections of ‘P cells’ in the PB from relatives of schizophrenic patients lend support to this view.
9.5. Inflammation markers
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suggest, that inflammatory processes during an acute psychotic episode are not responsible for the
brain substance loss which has previously been demonstrated neuroradiologically in schizophrenia.
Neuronal degeneration due to inflammation is the basic pathophysiological event in some, but not
all, CNS diseases, and the specific features of CNS immunological dynamics are probably part of
the dilemma of brain substance changes without gliosis which is included in the complex of
schizophrenia. The rapidly increasing knowledge about programmed cell death with apoptosis and
dendritic pruning may offer better explanations for the immunological aberrations detected in
schizophrenia.
The lack of evidence of inflammatory processes in the CNS of schizophrenic patients diverts
attention from conventional immunological reactions towards more complex sequences of apoptosis
and dendritic pruning in the pathophysiology of this disease. Preliminary findings of elevated
concentrations of free ICAM-5 (telencephalin) in the CSF of a subgroup of schizophrenic patients
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with parallel high frequencies of macrophages (Nikkilä et al 		
) lends support to this
view.
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10. SUMMARY AND CONCLUSIONS
A series of studies was undertaken to elucidate the role of immunocompetent cells in schizophrenia
by analyzing the mononuclear cell counts and distributions, as well as T lymphocyte subsets in the
CSF samples of first-admission and re-entry patients in the acute phase of the illness. Also the
concentrations of inflammation markers neopterin and MIP-1α were measured in order to clarify
the possible inflammatory mechanisms in the pathophysiology of schizophrenia.
The finding of the enrichment of mononuclear cells from the mononuclear phagocyte / macrophage
lineage in the CSF of schizophrenic patients suggests that mobilization of microglia is a
pathophysiological event that takes place during the schizophrenic process. This novel observation
may provide support to the neuroradiologically demonstrated loss of brain substance in
schizophrenia, and help to explain the subtle progressive brain transformation without marked
gliosis, which is still one of the most controversial topics in schizophrenia research.
The appearance of lymphocytes with atypical morphological features in the CSF reinforces the
previous interesting but disputable detection of lymphocyte abnormalities in schizophrenia. The
constancy of this finding, regarding the duration of the illness or the medicational status of the
patients, indicates that it is a marker of a trait rather than of a state in schizophrenia, and has thus
potential to be a susceptibility marker of the disease.
T lymphocyte subsets appear to display wide-range divergency in the CSF of schizophrenic patients
in the initial phase of the illness, and a tendency towards CD8+ dominance in the group of patients
with a more advanced form of the disease. This may signify an unspecific immunological
imbalance due to stress factors, meningeal irritation, etc. Also diffuse traffic of these cells across the
BBB, induced by macrophages / microglial mobilization, is a possible explanation for this finding.
However, the significance and specificity of this finding in the pathophysiology of schizophrenia
remain open until the methodology is developed sufficiently to ensure the reliability of flow
cytometric investigations of CSF cells.
The negative findings regarding the intrathecal inflammatory activity measured by two sensitive
inflammation markers strengthen the view that the detected aberrations of immunocompetent cells
are not a reflection of conventional immunological reactions with an inflammatory response taking
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place in the acute or subacute phase of schizophrenia. This tempts one to speculate that the
neuropathology of schizophrenia may be based on deviant sequences of programmed cell death
(apoptosis and dendritic pruning) during the neuronal development of genetically susceptible
individuals.
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